Abstract
Prostate cancer (PC) is the second most diagnosed cancer in our environment and the second most prevalent cancer. We use the term hormone-sensitive to refer to prostate cancer that has not been treated with androgen deprivation therapy (TPA). Abiraterone is a selective inhibitor of the enzyme 17-α-hydroxylase / C17, 20-lyase (CYP17) required for androgen biosynthesis in testicular, adrenal and prostate tumor tissues.
Keywords
Abiraterona; Prostate cancer; Metastatic disease
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Abiraterona per al tractament de càncer de pròstata hormonosensible metastàtic d’alt risc. Barcelona: Servei Català de la Salut; 2020.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/5754This item appears in following collections
The following license files are associated with this item: